A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

NCT04578548 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

66

Enrollment

INDUSTRY

Sponsor class

Stopped The study was early terminated due to lack of efficacy.

Conditions

Autosomal Dominant Polycystic Kidney Disease

Interventions

DRUG: GLPG2737
DRUG: Placebo

Sponsor

Lakefront Biotherapeutics NV